What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report a material definitive agreement, specifically the company's entry into a purchase agreement for a public offering of its common stock. It also includes an 'Other Events' section to announce the pricing of this offering and provides details about the associated press release.

How much capital is Vertex Pharmaceuticals expected to raise from this offering?

Vertex Pharmaceuticals is expected to raise approximately $300.3 million from the sale of 9,100,000 shares at $33.00 per share, before considering any potential exercise of the over-allotment option. If the underwriters exercise their option to purchase an additional 900,000 shares, the total gross proceeds could reach approximately $330.3 million.

What is the over-allotment option and what does it signify?

The over-allotment option, also known as a 'greenshoe' option, grants the underwriters the right to purchase up to an additional 900,000 shares of common stock from Vertex Pharmaceuticals at the offering price within 30 days. This option is typically included to help stabilize the stock price in the aftermarket and is often exercised if there is strong demand for the shares.

Where can investors find more detailed information about the offering?

Investors can find more detailed information about the offering in the Purchase Agreement (Exhibit 1.1) and the accompanying prospectus and prospectus supplement, which have been filed with the Securities and Exchange Commission. The press release (Exhibit 99.1) also provides key announcements regarding the pricing.

VRTX 8-K: Material Agreements

Summary

Vertex Pharmaceuticals Incorporated (VRTX) has filed an 8-K report on September 14, 2006, detailing a significant equity offering. The company entered into a purchase agreement with underwriters, including Merrill Lynch, Morgan Stanley, and UBS, to sell 9,100,000 shares of its common stock at a public offering price of $33.00 per share. This transaction is expected to provide the company with substantial capital for its operations and strategic initiatives. The offering also includes an over-allotment option for the underwriters to purchase an additional 900,000 shares, indicating strong market demand and confidence in the company's prospects. The company also announced the pricing of this common stock offering via a press release on September 14, 2006. This filing provides transparency to investors regarding material corporate changes and financial transactions. The details of the purchase agreement and the prospectus supplement outline the terms and conditions of the offering, which is crucial for investors to understand the potential dilution and the use of proceeds from this equity raise.

Key Highlights

1Vertex Pharmaceuticals priced a public offering of 9,100,000 shares of common stock.
2The offering price for each share was set at $33.00.
3The company entered into a Purchase Agreement with prominent underwriters: Merrill Lynch, Morgan Stanley, and UBS Securities.
4An over-allotment option was granted to the underwriters, allowing them to purchase up to an additional 900,000 shares.
5The offering is being conducted through a prospectus supplement dated September 14, 2006, and an accompanying prospectus dated September 11, 2006.
6A press release announcing the pricing of the common stock offering was issued on September 14, 2006.
7This 8-K filing serves to report a material definitive agreement related to the equity offering.

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Material Agreement (Sep 15, 2006)

Summary

Key Highlights

Frequently Asked Questions